XL177A (GMP)

Overview

XL177A GMP is XL177A ( HY-138794 ) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. XL177A is a covalent USP7 inhibitor that blocks the deubiquitinase activity of USP7 . XL177A destabilizes non-canonical PRC1 complexes or KDM6A and reduces chromatin deposition of H2AK119Ub , thereby relieving the repression of neuronal differentiation programs. Meanwhile, XL177A also regulates the ELOF1-UVSSA-USP7 -nuclear β-catenin axis, decreasing the transcription levels of related proteins and the accumulation of nuclear β-catenin . XL177A exerts antiviral effects by reducing the expression levels of coronavirus receptors, and exhibits inhibitory activity against APC -mutated colorectal cancer cells, neuroblastoma, and coronaviruses including SARS-CoV-2 variants. XL177A is mainly used in studies related to colorectal cancer , neuroblastoma, and coronavirus infections.

Application

Products | Products > GMP Small Molecules | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Deubiquitinase | Products > Signaling Pathways > SARS-CoV | Products > Signaling Pathways > Histone Demethylase

Product Information

• Catalog No.: HY-138794G
• CAS No.: 2417089-74-6
• Molecular Formula: C48H57ClN8O5
• Molecular Weight: 861.47
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source